Advertisement

Chemomab Therapeutics Ltd. CMMB

Set alert

Price alert · CMMB

All alert types
1.16 USD +0.04 +3.57%

At close · Oct 30

1.14 -0.02 -1.72%

After hours · Oct 30, 6:14 PM ET

Bid
1.12 × 1
Ask
1.16 × 1
1.02 Day range 1.16
1.00 52-week range 3.06
YTD
-29.70%
1 year
-61.07%
Open
1.14
Prev close
1.12
Mkt cap
8.50M
Vol
224.83K
Avg vol
96.62K
EPS
-1.04
P/E
0.00
Div yield
0.00%
More statistics
Low
1.02
High
1.16
Forward P/E
-41.25
Beta
0.30
Short ratio
1.15
Inst. own
27.99%
Dividend
0.00
Ex-div date
Earnings
Aug 21, 2024
50-d avg
1.57
200-d avg
1.23
1y target
8.00

2Y chart

Chart tools
Interval

Events in this range
  • Nov 14, 2024Earnings: -0.2; estimate -0.2; surprise 0%
  • Nov 15, 2024Rating: Oppenheimer · Outperform → Outperform
  • Aug 26, 2025Split: 1 for 4
Signals (80)
NameDateAgo
MACD: Buy SignalOct 27, 20264 days ago
RSI: OversoldOct 16, 20262 weeks ago
RSI: OversoldOct 13, 20262 weeks ago
RSI: OversoldOct 7, 20263 weeks ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 28, 20261 month ago
RSI: OversoldSep 28, 20261 month ago
MACD: Sell SignalSep 10, 20261 month ago
RSI: OverboughtAug 21, 20262 months ago
SMA: BullishAug 7, 20262 months ago
SMA: BullishAug 5, 20262 months ago
MACD: Buy SignalAug 3, 20262 months ago
MACD: Sell SignalJul 13, 20263 months ago
SMA: BearishJul 10, 20263 months ago
SMA: BearishJul 8, 20263 months ago
SMA: BullishJul 2, 20264 months ago
RSI: OverboughtJul 2, 20264 months ago
SMA: BullishJul 1, 20264 months ago
MACD: Buy SignalJul 1, 20264 months ago
SMA: BearishJun 12, 20264 months ago
MACD: Sell SignalJun 3, 20265 months ago
SMA: BullishMay 21, 20265 months ago
MACD: Buy SignalMay 21, 20265 months ago
MACD: Sell SignalMay 19, 20265 months ago
SMA: BearishMay 14, 20265 months ago
SMA: BullishMay 6, 20265 months ago
MACD: Buy SignalMay 5, 20265 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BullishApr 13, 20266 months ago
SMA: BearishApr 9, 20266 months ago
MACD: Buy SignalApr 9, 20266 months ago
SMA: BullishApr 8, 20266 months ago
SMA: BearishMar 23, 20267 months ago
MACD: Sell SignalMar 20, 20267 months ago
SMA: BullishFeb 27, 20268 months ago
MACD: Buy SignalJan 6, 20269 months ago
RSI: OversoldDec 24, 202510 months ago
RSI: OversoldDec 18, 202510 months ago
MACD: Sell SignalDec 12, 202510 months ago
MACD: Buy SignalNov 28, 202511 months ago
SMA: BearishNov 3, 202512 months ago
SMA: BullishOct 31, 20251 year ago
SMA: BearishOct 30, 20251 year ago
SMA: BullishOct 28, 20251 year ago
SMA: BearishOct 27, 20251 year ago
SMA: BullishOct 24, 20251 year ago
MACD: Sell SignalOct 23, 20251 year ago
SMA: BearishOct 22, 20251 year ago
SMA: BullishOct 7, 20251 year ago
RSI: OverboughtOct 7, 20251 year ago
MACD: Buy SignalSep 26, 20251 year ago
MACD: Sell SignalSep 16, 20251 year ago
MACD: Buy SignalSep 11, 20251 year ago
RSI: OversoldAug 21, 20251 year ago
RSI: OversoldJul 31, 20251 year ago
MACD: Sell SignalJul 21, 20251 year ago
MACD: Buy SignalJul 10, 20251 year ago
SMA: BearishJun 11, 20251 year ago
MACD: Sell SignalJun 2, 20251 year ago
MACD: Buy SignalMay 16, 20251 year ago
SMA: BullishMay 15, 20251 year ago
SMA: BearishMay 14, 20251 year ago
MACD: Sell SignalMay 14, 20251 year ago
SMA: BullishMay 9, 20251 year ago
SMA: BearishMay 6, 20251 year ago
SMA: BullishApr 30, 20251 year ago
SMA: BearishApr 29, 20251 year ago
SMA: BullishApr 28, 20251 year ago
MACD: Buy SignalApr 11, 20251 year ago
RSI: OversoldApr 10, 20251 year ago
RSI: OversoldApr 8, 20251 year ago
RSI: OversoldApr 1, 20251 year ago
MACD: Sell SignalMar 25, 20251 year ago
MACD: Buy SignalMar 17, 20251 year ago
RSI: OversoldMar 4, 20251 year ago
RSI: OversoldFeb 25, 20251 year ago
SMA: BearishFeb 18, 20251 year ago
MACD: Sell SignalJan 14, 20251 year ago
RSI: OverboughtJan 6, 20251 year ago
MACD: Buy SignalDec 26, 20241 year ago

Key statistics

Market cap
31.11M
Enterprise value
447.13M
Trailing P/E
0.00
Forward P/E
-41.25
PEG ratio
0.00
Price / sales
0.00
Price / book
1.38
EPS (TTM)
-0.94
Beta
0.30
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-11.36M
Total cash
12.73M
Total debt
360.00K
Return on equity
-93.80%
Shares outstanding
18.86M
Short % of float
0.87%
50-day average
1.57
200-day average
1.23

Analyst view

Consensus: none

Price target (mean) 8.00 +589.7% upside
Target (low)
4.00
Target (mean)
8.00
Target (high)
11.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 21, 2024

Expected Aug 21, 2024. Consensus EPS estimate -0.01.

Earnings history

Financials — quick view

All financials
CMMB Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CMMB Net income — quarterly -2.17M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CMMB EPS — quarterly -0.24
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CMMB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.20-0.200.000.00%
Aug 21, 2024Jun 1, 2024-0.20-0.26-0.06-30.00%
Aug 21, 2024Jun 1, 2024-0.20———
May 9, 2024Mar 1, 2024-0.20-0.28-0.08-40.00%
May 9, 2024Mar 1, 2024-0.20———
Mar 7, 2024Dec 1, 2023-0.40-0.26+0.14+35.00%

Upgrades / downgrades

CMMB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024OppenheimerreitOutperformOutperform
May 13, 2024Maxim Groupinit—Buy
May 6, 2024OppenheimerupPerformOutperform
Mar 8, 2024OppenheimermainPerformPerform
Oct 6, 2023Roth MKMinit—Buy
Jun 7, 2023OppenheimerdownOutperformPerform

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
chemomab.com

News

Your note

Sign in to keep a note on CMMB — it syncs with the Stock Master app.

Insider holders

CMMB insider holders
InsiderRelationLatest transactionDateShares held
MOR GEORGE ADIOfficer and DirectorSaleJan 2, 20230
ORBIMED ISRAEL GP LTD.Beneficial Owner of more than 10% of a Class of SecuritySaleJan 2, 20230

Institution ownership

CMMB institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.9.23%1,741,2732.87MSep 29, 2024
Sphera Funds Management Ltd.6.44%1,214,5752.00MSep 29, 2024
Yelin Lapidot Holdings Management Ltd.4.29%809,7171.34MSep 29, 2024
Morgan Stanley2.13%402,272663.75KSep 29, 2024
Ikarian Capital, LLC1.13%213,392352.10KSep 29, 2024
Two Sigma Securities, LLC0.21%39,93965.90KSep 29, 2024

Fund ownership

CMMB fund ownership
Holder% heldSharesValueReported
Blackstone Alternative Multi-Strategy Fund0.00%200329Jun 29, 2024
Advertisement